Recent findings from an innovative nationwide trial indicate that the drug pembrolizumab, when used in combination with standard therapy, may provide positive results for patients with locally advanced breast cancer.
Michael Birrer, a leading medical oncologist at Harvard University, will take the reins as the new director of the UAB Comprehensive Cancer Center, succeeding the retiring Edward Partridge.
The first target for the UAB spinoff Incysus Ltd. will be glioblastoma. Incysus has just received a European patent for its innovative approach to fighting cancer.
A UAB study shows specialized treatment sites contribute to better survival rates for those with acute leukemia. 
Research from UAB suggests that nearly half of children with the most common type of leukemia or their parents say they took more medications than they actually did.
UAB’s innovative Patient Care Connect Program utilizes lay navigation and provides a cost-effective new model for cancer care delivery.
The new UAB Integrative Medicine Clinic will provide conventional medical care with complementary approaches to tackle the biological, social and spiritual aspects of health and illness.
A key Leukemia & Lymphoma Society grant will provide an opportunity for a UAB researcher to develop a new immunotherapy treatment approach for the leukemia most prevalent in Western countries.
UAB Hospital has received a 2016 Women’s Choice Award and is named one of America’s Best Breast Centers.
A significant new UAB study published in Cancer shows that key socioeconomic factors, not race, affect survival of younger multiple myeloma patients.
Page 1 of 4